Abiraterone plus prednisone prolongs overall survival relative to prednisone alone in patients with metastatic castration-resistant prostate cancer who have disease progression after treatment with docetaxel. The survival gain observed in this pivotal trial is accomplished with few adverse events and conclusively demonstrates that patients with castration levels of serum testosterone remain sensitive to additional hormonal manipulation.
This is a preview of subscription content, log in via an institution to check access.
References
de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).
Huggins, C. & Hodges, C. V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection, on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293–297 (1941).
The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N. Engl. J. Med. 311, 1281–1286 (1984).
Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513–1520 (2004).
Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).
Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).
de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154 (2010).
Bayer Press Server. Alpharadin significantly improves overall survival in phase III Trial in patients with castration-resistant prostate cancer that has spread to the bone [online], (2011).
Logothetis, C. et al. Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study. [abstract 4520]. J. Clin. Oncol. 29 (2011).
Scher, H. I. et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. [abstract LBA4517]. J. Clin. Oncol. 29 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
O. Sartor declares he is a consultant for Algeta, Bellicum, Centocor Biotech, Dendreon, Exelixis, GlaxoSmithKline, Medivation, Millinium/Takeda, Oncogenex, Pfizer, Sanofi-aventis and Teva. He declares he receives honoraria from Sanofi-aventis and Research Grants from Algeta, Centocor Biotech, Cougar, Dendreon, Exilixis, Millenium/Takeda, Sanofi-aventis and Serono. He also owns shares from Lilly and GlaxoSmithKline.
Rights and permissions
About this article
Cite this article
Sartor, O. Abiraterone prolongs survival in metastatic prostate cancer. Nat Rev Clin Oncol 8, 515–516 (2011). https://doi.org/10.1038/nrclinonc.2011.111
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.111
- Springer Nature Limited
This article is cited by
-
AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial
Cancer Immunology, Immunotherapy (2013)